Table 3.
Toxicity
Toxicity | % of Patients by Toxicity Grade |
|
---|---|---|
Grade 3 | Grade 4 | |
Hematologic | ||
Anemia | 3.1 | 1.6 |
Leukocytes | 20.3 | 9.4 |
Lymphopenia | 0 | 1.6 |
Neutropenia | 12.5 | 45.3 |
Thrombocytopenia | 9.4 | 4.7 |
Febrile neutropenia | 4.7 | 3.1 |
Nonhematologic | ||
Sinus bradycardia | 1.6 | 0 |
Hypotension | 0 | 1.6 |
LV diastolic dysfunction | 1.6 | 0 |
Fatigue/weakness | 14.1 | 0 |
Anorexia | 1.6 | 0 |
Dehydration | 4.7 | 0 |
Diarrhea | 6.3 | 0 |
Mucositis | 1.6 | 0 |
Nausea/vomiting | 6.3 | 0 |
Infection | 1.6 | 0 |
Hypocalcemia | 1.6 | 1.6 |
Hyponatremia | 9.4 | 1.6 |
Hypokalemia | 1.6 | 0 |
Ataxia/walking | 3.1 | 0 |
Dizziness | 1.6 | 0 |
Dyspnea | 0 | 1.6 |
Musculoskeletal | 7.8 | 0 |
Bevacizumab associated | ||
Hypertension | 7.8 | 0 |
Cardiac ischemia | 0 | 1.6 |
Pulmonary hemorrhage | 1.6 | 0 |
Abdominal hemorrhage | 1.6 | 0 |
Epistaxis | 9.4 | 0 |
Thrombosis/embolism | 0 | 1.6 |
NOTE. Total number of patients = 64. Two grade 5 toxicities occurred: one patient experienced multiorgan failure, and one patient experienced lung infection and grade 3 to 4 neutropenia.
Abbreviation: LV, left ventricle.